PubMed Health⌕ Search

PubMed · 15185638

[Functional insulin therapy].

Abstract

This concept has been developed since 1983 in Germany and Austria. It is of greatest interest with regard to a pedagogical approach of insulin therapy in type 1 diabetic patients. The goal of functional insulin therapy is to separate basal and prandial insulin requirements. The patients perform the following experimental sessions in order to establish their own insulin requirements: 24 h fasting to assess the basic insulin requirement, ingestion of test meals containing different amounts of carbohydrates to determine the individual carbohydrate-intake/insulin requirement relationship, determination of an individual correction algorithm to decrease an elevated blood glucose level (1.60 g/L). It involves patient's therapeutic education, frequent self monitoring blood glucose (6 to 8 daily controls), multiple daily insulin injections. This concept has to be adapted to patient's desire of self responsibility and autonomy. Functional insulin therapy improves metabolic control, decreases the frequency of mild and severe hypoglycaemia, it enhances self-esteem in diabetic patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Claude Sachon. 2003-06-01. [Functional insulin therapy].. https://pubmed.ncbi.nlm.nih.gov/15185638/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues.

The purification of animal insulin preparations and the use of human recombinant insulin have markedly reduced the incidence but not completely suppressed the occurrence of insulin allergy manifestations. Advances in technologies concerning the mode of delivery of insulin, i.e. continuous subcutaneous insulin infusion (CSII), and the use of insulin analogues, resulting from the alteration in the amino acid sequence of the native insulin molecule, may influence the immunogenicity and antigenicity of native insulin. Instead of increasing allergy reactions, CSII has been reported to represent a successful alternative treatment in diabetic patients presenting local or generalized allergy to insulin or other components (zinc, protamine) of conventional treatment. Most recent reports concern CSII-treated patients using short-acting insulin analogues (essentially insulin lispro), although the precise role of these insulin analogues remains unclear as allergy to them has also been described. Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present.

Diabetes Mellitus↗

Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease.

Insulin deficiency is known to be associated with a state of increased muscle protein breakdown; this process is mediated by the ubiquitin-proteasome pathway. Convincing in vitro data are further supported by extensive studies in humans with insulin deprivation and are further substantiated by reversal of muscle protein breakdown with insulin treatment. In patients with end-stage renal disease (ESRD) and diabetes mellitus (DM), muscle protein breakdown is enhanced in both acute and chronic conditions. Recent data also point to the potential protein catabolic effects of insulin resistance combined with insulin deficiency. Because ESRD is associated with a state of insulin resistance, uremic muscle wasting may also be mediated by this pathway.

Diabetes Mellitus↗